ChilliPharm Data-driven insights: How digital media can help clinical trials succeed

Allison Morgan (1).png

In this blog, Allison Morgan, Clinical Development Consultant at Chillipharm summaries the  newly published White Paper from ChilliPharm which highlights how the power of digital media can be harnessed to provide real world evidence by combining traditional clinical data sources with untraditional ones such as videos, audio files, and photographs which can transform the evaluation of new therapeutics, offering a deeper understanding of diseases and capturing the patient experience like never before.

The filming or photographing of endpoint assessments and milestones at key stages throughout a trial can provide invaluable visual evidence of the efectiveness of the compound being trialled. However, compliance and privacy are paramount in this digital landscape, where personal information must be safeguarded, and strict regulations and protocols must be adhered to. ChilliPharm’s specialist video platform and anonymisation and redaction services ensure that this vital visual evidence can be securely and compliantly shared with stakeholders and regulatory authorities, helping to accelerate regulatory approvals.

ChilliPharm’s publication examines the ethical considerations, the challenges of data protection, and the need for strict compliance. Discover how using clinical digital assets are revolutionizing the way we conduct research, elevating the patient voice with visual evidence, and shaping the future of both drug and device evaluation and approval.

The paper outlines the rapidly growing field of real world evidence that is paving the way for enhanced healthcare outcomes and will help you embrace the digital revolution and embark on a journey where data meets compassion, innovation meets compliance, and patients are at the heart of it all.

About Chillipharm 

ChilliPharm provides unique end-to-end compliant services that enable the capture, management and de-identification of video evidence in clinical outcome assessments to increase regulatory submission success.


More news and updates 

CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.

Autumn Statement 2023 analysis

The Chancellor has delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

Member spotlight: meet the Bio-Based and Biodegradable Industries Association

The Bio-Based and Biodegradable Industries Association (BBIA) and The BioIndustry Association (BIA) enter a mutual membership agreement to strengthen collaboration and support each other's work and member communities.

Bioprocessing: Unraveling the future by examining the past

Over the past two decades, the landscape of biopharmaceuticals in the UK has undergone a significant transformation.

CEO Update - 20 November 2023

London Life Sciences Week last week had an amazing buzz. I think there were more Americans in life science over for one week than I’ve ever experienced – centred on the Jefferies Healthcare Conference. At the same time, London was also full of Europeans at events like the Scrip Awards, where Jeremy Levin received the Lifetime Achievement Award and gave an impactful speech. The connectivity was immense - with a massive range of events that were really vibrant, diverse and inclusive.

London Life Sciences Week: connecting the global biotech community

London Life Sciences Week united the global biotech community for a dynamic week of networking and dealmaking. The BIA representatives were out and about throughout the week, networking with members and stakeholders. In this blog, Steve Bates OBE, CEO of BioIndustry Association, summarises insights based on the BIA team's first-hand experience.

ChilliPharm Data-driven insights: How digital media can help clinical trials succeed

Unleashing the potential of digital media in clinical trials: compliance by design

Future of UK Regulation Conference 2023: Novel technologies

BIA Future of UK Regulation Conference 2023: Novel technologies

mRNA Revolution: eXmoor case study

In this case study, the BIA's report mRNA Revolution: A new generation of medicine explores eXmoor's biomanufacturing offerings, including its facilities and expertise and its commercialisation lab facilities in Bristol. 


More within